Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naproxen Sodium,Sumatriptan

            Therapeutic Area: Neurology Product Name: Suvexx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Orion Corporation

            Deal Size: Undisclosed Upfront Cash: $2.0 million

            Deal Type: Partnership December 21, 2020

            Details:

            Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rizatriptan Benzoate

            Therapeutic Area: Neurology Product Name: Rizaport

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exeltis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 27, 2020

            Details:

            Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Tetracaine

            Therapeutic Area: Neurology Product Name: Pliaglis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries Ltd.

            Deal Size: Undisclosed Upfront Cash: $3.9 million

            Deal Type: Licensing Agreement July 28, 2020

            Details:

            The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rizatriptan Benzoate

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2020

            Details:

            IntelGenx recently received from the U.S. FDA Complete Response Letter regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®.